Compass Therapeutics, Inc. (CMPX) vs Zentalis Pharmaceuticals, Inc. (ZNTL)
A side-by-side comparison of Compass Therapeutics, Inc. and Zentalis Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CMPX
Compass Therapeutics, Inc.
$1.00HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
ZNTL
Zentalis Pharmaceuticals, Inc.
$2.67HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CMPX vs ZNTL
growth of $100 · dividends reinvested · last 6yCMPX -88.7% (-30.5%/yr)ZNTL -93.6% (-36.7%/yr)CMPX compounded faster over this window
CMPX ZNTL
CMPX vs ZNTL: by the numbers
- •ZNTL is the larger company ($190M vs $180M market cap).
Metrics side by side
Valuation
| Metric | CMPX | ZNTL |
|---|---|---|
| P/B ratio | 1.08 | 1.32 |
Profitability
| Metric | CMPX | ZNTL |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -44.23% | -121.76% |
| ROIC | -46.59% | -105.17% |
Growth (annualized)
| Metric | CMPX | ZNTL |
|---|---|---|
| Total return CAGR (5Y) | -22.79% | -47.34% |
Frequently asked
- How have CMPX and ZNTL total returns compared?
- Over the past 5 years, CMPX delivered -22.79% and ZNTL delivered -47.34% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.